Biotek-snakken — December 2024
-
Biovica signs agreement with American health giant - Biovica International AB
Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in the US, with revenues exceeding 100 billion USD. The company is both a health insurance and a health care service provider serving over 10 million Americans through […]
Biovica International AB (biovica.com)
-
Saniona banker bare videre op, men selskabet er også kraftigt underpriset efter aftalen kom med Acadia i torsdags. CEO Thonas Feldthaus taler på en konference i morgen og Redeye kommer med opdateret kursmål samme dag. Før aftalen var kursmålet 6 SEK, så efter aftalen er det helt sikkert 2-cifret og så kan der være en aftale mere på vej, samtidig med at Tesofensine kan blive godkendt i Mexico anytime, så mit kursmål nedenfor på 25-30 SEK er slet ikke så urealistisk og vi ligger og roder i 7,82 nu
-
Jonas2, jeg er helt enig, men ingen tvivl om, at endnu en partneraftale er blevet nemmere nu og her ligger SAN2355 lige for og den vurderes til at være endnu mere værd, end den aftale som de netop har indgået med Acadia omkring SAN711
Udover dette, så skal de nok få en godkendelse i land omkring Tesofensine i Mexico, så at man kan købe aktien til 7,60 SEK er virkelig et godt tilbud. -
-
Biotekfirma gør klar til børsentré med nye profiler i bestyrelsen https://borsen.dk/nyheder/virksomheder/biotekfirma-gor-klar-til-borsentre-med-nye-profiler-i-bestyrelsen?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
Why NovoCure Stock Was Winning Big This Week https://proinvestor.com/investornyt/1251361/why-novocure-stock-was-winning-big-this-week
-
Infant Bacterial Therapeutics data fra undersøgelsen vil blive præsenteret på Hot Topics in Neonatology, i dag den 9. december af professor Josef Neu. https://hottopicsinneonatology.nemours.org/
-
Bud på: Abliva - oppe med +200% i dag ...
Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases.
(abliva.com)
Research & Development
Research & Development – Abliva
Abliva’s in-house R&D capabilities have been instrumental in creating and delivering a portfolio that includes several projects with mechani ...
(abliva.com)
-
Medivir obtains IND approval for fostrox - the first oral, liver-targeted treatment for advanced liver cancer
Jeg har taget en pæn position i svenske Medivir i dag med baggrund i deres pressemeddelelse. Skrevet efter luk ...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind